Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 162

Similar articles for PubMed (Select 22234006)

1.

Controversies in using urine samples for Prostate Cancer detection: PSA and PCA3 expression analysis.

Fontenete S, Silva J, Teixeira AL, Ribeiro R, Bastos E, Pina F, Medeiros R.

Int Braz J Urol. 2011 Nov-Dec;37(6):719-26.

2.

The diagnostic value of PCA3 gene-based analysis of urine sediments after digital rectal examination for prostate cancer in a Chinese population.

Shen M, Chen W, Yu K, Chen Z, Zhou W, Lin X, Weng Z, Li C, Wu X, Tao Z.

Exp Mol Pathol. 2011 Feb;90(1):97-100. doi: 10.1016/j.yexmp.2010.10.009. Epub 2010 Oct 20.

PMID:
20970419
3.

A three-gene panel on urine increases PSA specificity in the detection of prostate cancer.

Rigau M, Ortega I, Mir MC, Ballesteros C, Garcia M, Llauradó M, Colás E, Pedrola N, Montes M, Sequeiros T, Ertekin T, Majem B, Planas J, Ruiz A, Abal M, Sánchez A, Morote J, Reventós J, Doll A.

Prostate. 2011 Dec;71(16):1736-45. doi: 10.1002/pros.21390. Epub 2011 Apr 25.

PMID:
21520154
4.

PCA3 sensitivity and specificity for prostate cancer detection in patients with abnormal PSA and/or suspicious digital rectal examination. First Latin American experience.

Ramos CG, Valdevenito R, Vergara I, Anabalon P, Sanchez C, Fulla J.

Urol Oncol. 2013 Nov;31(8):1522-6. doi: 10.1016/j.urolonc.2012.05.002. Epub 2012 Jun 9.

PMID:
22687565
5.

APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer.

Groskopf J, Aubin SM, Deras IL, Blase A, Bodrug S, Clark C, Brentano S, Mathis J, Pham J, Meyer T, Cass M, Hodge P, Macairan ML, Marks LS, Rittenhouse H.

Clin Chem. 2006 Jun;52(6):1089-95. Epub 2006 Apr 20.

6.

PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy.

Marks LS, Fradet Y, Deras IL, Blase A, Mathis J, Aubin SM, Cancio AT, Desaulniers M, Ellis WJ, Rittenhouse H, Groskopf J.

Urology. 2007 Mar;69(3):532-5.

PMID:
17382159
7.

The role of urine prostate cancer antigen 3 mRNA levels in the diagnosis of prostate cancer among Hong Kong Chinese patients.

Ng CF, Yeung R, Chiu PK, Lam NY, Chow J, Chan B.

Hong Kong Med J. 2012 Dec;18(6):459-65.

8.

PSGR and PCA3 as biomarkers for the detection of prostate cancer in urine.

Rigau M, Morote J, Mir MC, Ballesteros C, Ortega I, Sanchez A, Colás E, Garcia M, Ruiz A, Abal M, Planas J, Reventós J, Doll A.

Prostate. 2010 Dec 1;70(16):1760-7. doi: 10.1002/pros.21211.

PMID:
20672322
9.

PCA3 urine mRNA testing for prostate carcinoma: patterns of use by community urologists and assay performance in reference laboratory setting.

Shappell SB, Fulmer J, Arguello D, Wright BS, Oppenheimer JR, Putzi MJ.

Urology. 2009 Feb;73(2):363-8. doi: 10.1016/j.urology.2008.08.459. Epub 2008 Nov 8.

PMID:
18995890
10.

Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer.

Salami SS, Schmidt F, Laxman B, Regan MM, Rickman DS, Scherr D, Bueti G, Siddiqui J, Tomlins SA, Wei JT, Chinnaiyan AM, Rubin MA, Sanda MG.

Urol Oncol. 2013 Jul;31(5):566-71. doi: 10.1016/j.urolonc.2011.04.001. Epub 2011 May 19.

11.

A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy.

Auprich M, Augustin H, Budäus L, Kluth L, Mannweiler S, Shariat SF, Fisch M, Graefen M, Pummer K, Chun FK.

BJU Int. 2012 Jun;109(11):1627-35. doi: 10.1111/j.1464-410X.2011.10584.x. Epub 2011 Sep 21.

PMID:
21939492
12.

Contemporary role of prostate cancer antigen 3 in the management of prostate cancer.

Auprich M, Bjartell A, Chun FK, de la Taille A, Freedland SJ, Haese A, Schalken J, Stenzl A, Tombal B, van der Poel H.

Eur Urol. 2011 Nov;60(5):1045-54. doi: 10.1016/j.eururo.2011.08.003. Epub 2011 Aug 25. Review.

PMID:
21871709
13.

Molecular PCA3 diagnostics on prostatic fluid.

van Gils MP, Cornel EB, Hessels D, Peelen WP, Witjes JA, Mulders PF, Rittenhouse HG, Schalken JA.

Prostate. 2007 Jun 1;67(8):881-7.

PMID:
17440939
14.

The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance.

van Gils MP, Hessels D, van Hooij O, Jannink SA, Peelen WP, Hanssen SL, Witjes JA, Cornel EB, Karthaus HF, Smits GA, Dijkman GA, Mulders PF, Schalken JA.

Clin Cancer Res. 2007 Feb 1;13(3):939-43.

15.

Biopsy and radical prostatectomy pathological patterns influence Prostate cancer gene 3 (PCA3) score.

De Luca S, Passera R, Bollito E, Milillo A, Scarpa RM, Papotti M, Coda R, Randone DF.

Anticancer Res. 2013 Oct;33(10):4657-62.

PMID:
24123045
17.

DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer.

Hessels D, Klein Gunnewiek JM, van Oort I, Karthaus HF, van Leenders GJ, van Balken B, Kiemeney LA, Witjes JA, Schalken JA.

Eur Urol. 2003 Jul;44(1):8-15; discussion 15-6.

PMID:
12814669
18.

Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy.

Haese A, de la Taille A, van Poppel H, Marberger M, Stenzl A, Mulders PF, Huland H, Abbou CC, Remzi M, Tinzl M, Feyerabend S, Stillebroer AB, van Gils MP, Schalken JA.

Eur Urol. 2008 Nov;54(5):1081-8. doi: 10.1016/j.eururo.2008.06.071. Epub 2008 Jun 26.

PMID:
18602209
19.

The combination of urine DD3(PCA3) mRNA and PSA mRNA as molecular markers of prostate cancer.

Mearini E, Antognelli C, Del Buono C, Cochetti G, Giannantoni A, Nardelli E, Talesa VN.

Biomarkers. 2009 Jun;14(4):235-43. doi: 10.1080/13547500902807306.

PMID:
19489685
20.

PCA3: from basic molecular science to the clinical lab.

Day JR, Jost M, Reynolds MA, Groskopf J, Rittenhouse H.

Cancer Lett. 2011 Feb 1;301(1):1-6. doi: 10.1016/j.canlet.2010.10.019. Epub 2010 Nov 18. Review.

PMID:
21093148
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk